Utilize este identificador para referenciar este registo: http://hdl.handle.net/10316/91058
Título: Intravitreal injection of adenosine A2A receptor antagonist reduces neuroinflammation, vascular leakage and cell death in the retina of diabetic mice
Autor: Inês Dinis Aires
Maria Helena Madeira
Raquel Boia
Ana Catarina Rodrigues-Neves
Joana Margarida Martins
António Francisco Ambrósio
Ana Raquel Santiago
Palavras-chave: Nitric-Oxide Synthase; Ganglion-Cells; Microglial activation; Retinopathy; Rat; Inflammation; Model; Neurodegeneration; Degeneration; Apoptosis
Data: 20-Nov-2019
Editora: NATURE PUBLISHING GROUP
Projeto: Bayer AG 
European Union (EU) 
Portuguese Foundation for Science and Technology 
Centro 2020 Regional Operational Programme (BRAINHEALTH 2020) 
Título da revista, periódico, livro ou evento: Scientific Reports
Volume: 9
Número: 17207
Local de edição ou do evento: MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
Resumo: Diabetic retinopathy is a major complication of diabetes mellitus and a leading cause of blindness. The pathogenesis of diabetic retinopathy is accompanied by chronic low-grade inflammation. Evidence shows that the blockade of adenosine A2A receptors (A2AR) affords protection to the retina through the control of microglia-mediated neuroinflammation. Herein, we investigated the therapeutic potential of an antagonist of A2AR in a model of diabetic retinopathy. Type 1 diabetes was induced in 4-5 months old C57BL/6 J mice with a single intraperitoneal injection streptozotocin. Animals were treated one month after the onset of diabetes. The A2AR antagonist was delivered by intravitreal injection once a week for 4 weeks. Microglia reactivity and inflammatory mediators were increased in the retinas of diabetic animals. The treatment with the A2AR antagonist was able to control microglial reactivity and halt neuroinflammation. Furthermore, the A2AR antagonist rescued retinal vascular leakage, attenuated alterations in retinal thickness, decreased retinal cell death and the loss of retinal ganglion cells induced by diabetes. These results demonstrate that intravitreal injection of the A2AR antagonist controls inflammation, affords protection against cell loss and reduces vascular leakage associated with diabetes, which could be envisaged as a therapeutic approach for the early complications of diabetes in the retina.
URI: http://hdl.handle.net/10316/91058
ISSN: 2045-2322
DOI: 10.1038/s41598-019-53627-y
Direitos: openAccess
Aparece nas coleções:I&D IBILI - Artigos em Revistas Internacionais

Ficheiros deste registo:
Ficheiro Descrição TamanhoFormato
41598_2019_Article_53627.pdf5.08 MBAdobe PDFVer/Abrir
Mostrar registo em formato completo

Visualizações de página

28
Visto em 24/set/2020

Downloads

1
Visto em 24/set/2020

Google ScholarTM

Verificar

Altmetric

Altmetric


Este registo está protegido por Licença Creative Commons Creative Commons